Raymond James & Associates Compugen LTD Transaction History

Raymond James & Associates

$150 Billion
Q2 2024

A detailed history of Raymond James & Associates transactions in Compugen LTD stock. As of the latest transaction made, Raymond James & Associates holds 84,625 shares of CGEN stock, worth $153,171. This represents 0.0% of its overall portfolio holdings.

Number of Shares

84,625

Previous 86,825 2.53%

Holding current value

$153,171

Previous $224,000 36.61%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 19, 2024	SELL	$1.68 - $2.52 $3,696 - $5,544	-2,200 Reduced 2.53%	84,625 $142,000
Q1 2024 Apr 22, 2024	SELL	$1.75 - $2.95 $10,150 - $17,110	-5,800 Reduced 6.26%	86,825 $224,000
Q4 2023 Jan 16, 2024	SELL	$0.53 - $2.0 $5,300 - $20,000	-10,000 Reduced 9.74%	92,625 $183,000
Q2 2023 Jul 25, 2023	SELL	$0.57 - $1.38 $570 - $1,380	-1,000 Reduced 0.97%	102,625 $116,000
Q4 2022 Feb 08, 2023	SELL	$0.58 - $1.2 $15,224 - $31,500	-26,250 Reduced 20.21%	103,625 $74,000
Q3 2022 Oct 25, 2022	SELL	$0.66 - $2.32 $6,303 - $22,156	-9,550 Reduced 6.85%	129,875 $85,000
Q2 2022 Aug 12, 2022	SELL	$1.57 - $3.33 $35,560 - $75,424	-22,650 Reduced 13.98%	139,425 $258,000
Q1 2022 May 11, 2022	SELL	$2.76 - $4.64 $141,960 - $238,658	-51,435 Reduced 24.09%	162,075 $522,000
Q4 2021 Feb 08, 2022	BUY	$4.09 - $7.16 $45,051 - $78,867	11,015 Added 5.44%	213,510 $918,000
Q3 2021 Nov 02, 2021	BUY	$5.8 - $8.02 $281,880 - $389,772	48,600 Added 31.58%	202,495 $1.21 Million
Q2 2021 Aug 11, 2021	BUY	$6.87 - $9.16 $92,745 - $123,660	13,500 Added 9.62%	153,895 $1.27 Million
Q1 2021 May 14, 2021	BUY	$7.67 - $13.77 $399,031 - $716,384	52,025 Added 58.87%	140,395 $1.21 Million
Q4 2020 Feb 12, 2021	SELL	$12.07 - $17.95 $206,469 - $307,052	-17,106 Reduced 16.22%	88,370 $1.07 Million
Q3 2020 Nov 04, 2020	BUY	$14.16 - $19.45 $62,063 - $85,249	4,383 Added 4.34%	105,476 $1.71 Million
Q2 2020 Jul 28, 2020	SELL	$6.97 - $17.12 $100,646 - $247,212	-14,440 Reduced 12.5%	101,093 $1.52 Million
Q1 2020 Apr 21, 2020	BUY	$5.79 - $11.83 $156,631 - $320,025	27,052 Added 30.57%	115,533 $839,000
Q4 2019 Feb 12, 2020	SELL	$3.9 - $6.16 $4,410 - $6,966	-1,131 Reduced 1.26%	88,481 $527,000
Q3 2019 Nov 07, 2019	BUY	$3.01 - $4.49 $18,601 - $27,748	6,180 Added 7.41%	89,612 $379,000
Q2 2019 Aug 06, 2019	SELL	$2.8 - $4.14 $1,120 - $1,655	-400 Reduced 0.48%	83,432 $329,000
Q1 2019 May 06, 2019	BUY	$2.35 - $4.19 $4,700 - $8,380	2,000 Added 2.44%	83,832 $347,000
Q4 2018 Feb 11, 2019	BUY	$2.17 - $3.8 $5,153 - $9,025	2,375 Added 2.99%	81,832 $178,000
Q3 2018 Nov 14, 2018	BUY	$3.0 - $4.05 $30,000 - $40,500	10,000 Added 14.4%	79,457 $306,000
Q2 2018 Aug 14, 2018	BUY	$3.15 - $4.7 $37,759 - $56,338	11,987 Added 20.86%	69,457 $229,000
Q1 2018 May 14, 2018	SELL	$2.5 - $4.45 $1,700 - $3,026	-680 Reduced 1.17%	57,470 $256,000
Q4 2017 Feb 14, 2018	BUY	$2.35 - $4.0 $10,222 - $17,400	4,350 Added 8.09%	58,150 $145,000
Q3 2017 Nov 13, 2017	SELL	$2.75 - $3.95 $2,750 - $3,950	-1,000 Reduced 1.82%	53,800 $202,000
Q2 2017 Aug 14, 2017	BUY	N/A	54,800	54,800 $208,000

Others Institutions Holding CGEN

# of Institutions

Shares Held

13.4M

Call Options Held

191K

Put Options Held

135K

View Full List

About COMPUGEN LTD

Ticker CGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 86,624,600
Market Cap $157M
Description
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tu...

More about CGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account

Raymond James & Associates Compugen LTD Transaction History